97 Street NW
Suite 4342
Edmonton, AB T6E 5R9
Canada
780-448-1400
https://www.questpharmatech.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees:
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Dr. Ragupathy Madiyalakan Ph.D. | CEO & Director | 215k | N/A | N/A |
Mr. Pierre Vermette C.A., CPA | Chief Financial Officer | 74.17k | N/A | N/A |
Mr. Roger Andrews | Head of Investor Relations & Corporate Communications | N/A | N/A | N/A |
Mr. Douglas C. Bachman | Vice President of Corporate Development | 37.94k | N/A | 1954 |
Mr. Thomas Woo | Vice President of Product Development | N/A | N/A | N/A |
Quest PharmaTech Inc., a pharmaceutical company, engages in the development of novel therapeutics for the treatment of targeted cancer. The company's lead product candidate is Mab AR 9.6 against truncated O-glycan on MUC16, for the potential cancer targets include pancreatic, colon, leukemia, ovarian, and breast cancer. It is also involved in the development of Oregovomab, which is in Phase III clinical trial for the treatment of ovarian cancer. The company is headquartered in Edmonton, Canada.
Quest PharmaTech Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.